Option chain shows key data for RenovoRx's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for RenovoRx.

RenovoRx (NASDAQ:RNXT) Stock, Option Chain

RenovoRx

RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.

Stock market analysts

News

Price Target

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

ARMK

DCBO

EXAS

RNXT

Exact Sciences To Rally Around 33%? Here Are 10 Top Analyst Forecasts For Thursday

movers image

Intraday Update

Movers

ADBE

BAND

BIMI

CABA

CANF

CNSP

CORT

FOXO

GANX

INAB

IONM

IRON

JFBR

KAVL

KITT

KYTX

LGVN

NAAS

NNVC

NVAX

OCUL

ONMD

PENN

POWW

RARE

RZLT

SVMH

THMO

TWOU

WLFC

Why AMMO Shares Are Trading Lower By Over 19%? Here Are Other Stocks Moving In Friday&#39;s Mid-Day Session

Penny Stocks

Small Cap

ADTX

ALLO

AMPX

AOSL

ARBK

AVXL

BROG

BTCS

BTDR

CLSK

DOGZ

GDRX

HLTH

KNSA

KORE

LBPH

LMDX

LYEL

MARA

MNKD

MOBX

MRNA

MSTR

PGEN

PRTC

RIOT

RIVN

SNES

SNGX

SNTG

SXTC

TBLT

VSTE

VTNR

VYGR

Shares of  Longboard Pharmaceuticals, Inc.

Why Longboard Pharmaceuticals Shares Are Trading Higher By Around 200%? Here Are Other Stocks Moving In Tuesday&#39;s Mid-Day Session

RenovoRx Inc

WIIM

ASNS

Actelis Networks shares are trading higher after the company announced two expansion orders from the Washington DC Department of Transportation.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/585aa876b5a482000151d0ee/kevin-grundy">Exane BNP Paribas analyst Kevin Grundy</a> initiated coverage on Constellation Brands, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STZ#NYSE">STZ</a>) with a Neutral rating and announced a price target of $261. Constellation Brands shares closed at $239.66 on Friday. <a href="https://www.benzinga.com/quote/STZ/analyst-ratings">See how other analysts view this stock.</a></li>
<li>TD Cowen analyst Joseph Thome initiated coverage on Viridian Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRDN#NASDAQ">VRDN</a>) with a Buy rating. Viridian Therapeutics shares closed at $20.20 on Friday. <a href="https://www.benzinga.com/quote/VRDN/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Canaccord Genuity analyst Edward Nash initiated coverage on Apogee Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APGE#NASDAQ">APGE</a>) with a Buy rating and announced a price target of $89. Apogee Therapeutics shares closed at $43.46 on Friday. <a href="https://www.benzinga.com/quote/APGE/analyst-ratings">See how other analysts view this stock.</a></li>
<li>UBS analyst Timothy Arcuri initiated coverage on Arm Holdings plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARM#NASDAQ">ARM</a>) with a Buy rating and announced a price target of $160. ARM shares closed at $135.99 on Friday. <a href="https://www.benzinga.com/quote/ARM/analyst-ratings">See how other analysts view this stock.</a></li>
<li>HC Wainwright &amp; Co. analyst Mitchell Kapoor initiated coverage on Sarepta Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) with a Sell rating and announced a price target of $80. Sarepta Therapeutics shares closed at $114.23 on Friday. <a href="https://www.benzinga.com/quote/srpt/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying SRPT stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="621" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25085724/image-268-1024x621.png" alt="" class="wp-image-663414" style="width:645px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25085724/image-268-1024x621.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25085724/image-268-300x182.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25085724/image-268-768x466.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25085724/image-268.png 1085w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/24/11/42137942/jim-cramer-says-this-stock-is-a-bitcoin-play-and-he-prefers-to-own-bitcoin">Jim Cramer Says This Stock Is A Bitcoin Play And He Prefers To Own Bitcoin</a></li>
</ul>

Initiation

APGE

SRPT

VRDN

This Sarepta Therapeutics Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Monday

AI, and specifically Generative AI with its ability for predictive analytics, is becoming a critical component of digital transformation and future business growth in almost all industries. Enterprise-grade data networks such as Verizon's will be instrumental in these processes, and Verizon continues to advance its network components to deliver on the promises of AI. In a recent trial in Boston, Verizon moved 1.6 Tb/s of data in its live fiber network on a single-carrier wavelength using <a href="https://www.globenewswire.com/Tracker?data=jEsaVB2cRTvK3bQqbyTHO0WZ7rGV6Qu4UgnYeJ6SxtN_4W-BZBlfjdBh34O8xVoBzGPGUPnsWwnc2VeDBgK_z1squs4lkiPD43cyhJp89LQHhxkBFwp9ztWYfoSj-5wBQ9yW8hUMf1OqKpN5YKbd3ikA1NCwioZaXHbWOK3yEDHTYxItAdo3NtR3o8Nt7Iy92cwJCAoob-856xQgiZwJgajud3S04kTfXQkZSmLilUzw715k6KbeGmzs4Niwfvn5BvPJK6e6SnUpZZVZzwrb1CyAM8twHYwLd50J5gRFFfViQ0DPUEFiI2pCngp3DkkEazk78a8DzBtkqjqNIgWEIebtCJjBdLpuE7OgwpZf46YBDAVuWNSbNmUNjjF66_fcqQUGq83OZsxHYLl7HltBVTcvceuz_mdGUXz-qnHxSScM1hdJoLlIqChXTjtZP6CgKqgoYpdbXAuJwZD1kGcBJcglFZ7w1i8RZteTvxF0iBiosrsQl8ru3ys_siIIHANXl-FGxMnX5RTQAdO-DYtOJA==">Ciena's</a>&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CIEN#NYSE">CIEN</a>) WaveLogic 6 Extreme (<a href="https://www.globenewswire.com/Tracker?data=KDfXHnLxFL6Ym-4uoiVOOK5wA1UpvHeruhAV72AO5TPZd3MSkVRXKc6u9vX1BYo-awwRn0n1j7u_Cg4iUJtKEoH_WTCjIrUMvZ7Yt2Yhj3VqQ05XqLRFywz0SfuWD7LcPwsTKpQAKs8ywklSgA5lM4nK-iGxrWkkaJkvmMHgfE-_gEzaXL64H21u2SzPjS1VGagX_QKjEu6rKviUFDuX6tk2iCJu2jR6sh3HQY5oSFai7hJQs2FMy9mnSZFlb484ngZAcA7bws7wXeBrV9SajMAcPCLzQt8M9yhN5YedR8I9Gk8pPUaw9ohwWR7UGbZpuThDbBIjzs3RFqgpyr-tv0_AIpYwhX8z0n-z6K1qDSDyWeUctrxZj5ShKn_xbSJSvaKt51MPdF2yQX3IC7Q2b4TVC8ANKNjwSXKxBzj0GLSUiBDr_FhQqtPjh9pXeQ-1A-_NE-lY0-3-QFlmne2ypuORdXuI7UE-pyIhb8duHONRkG8m1BWRGKJ0FRaxGTwosvWOotZZ0KqlHwweHsycvaNFhoVXK7sKkc1vpd607A8=">WL6e</a>) coherent optical solution. This next generation technology allows data traveling across Verizon's fiber network to travel farther and faster, leading to a better customer experience. In addition, the upgrade to this new equipment will result in higher reliability and significant energy savings in that portion of the fiber network.

CIEN

Verizon Advances Its Fiber Network For AI Workloads Using Ciena's WaveLogic 6, A Next Generation Technology That Allows Data Traveling Across Verizon's Fiber Network To Travel Farther And Faster

Mizuho analyst Ben Chaiken downgrades Red Rock Resorts (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RRR#NASDAQ">RRR</a>) from Outperform to Neutral and lowers the price target from $57 to $44.

Downgrades

Mizuho Downgrades Red Rock Resorts to Neutral, Lowers Price Target to $44

With just six weeks left in 2024, Senate Majority Leader <a href="https://www.benzinga.com/topic/chuck-schumer">Chuck Schumer</a> (D-NY) faces mounting criticism for failing to deliver on his <a href="https://www.benzinga.com/markets/cannabis/24/03/37526202/chuck-schumer-senate-will-work-very-hard-to-pass-cannabis-banking-bill-before-upcoming-elections">long-standing promise</a> of achieving cannabis banking reform. Now, he&#8217;s mounting a Hail Mary effort to get it across the finish line before the term ends.
Senators on Capitol <a href="https://login.politicopro.com/?redirect=https://subscriber.politicopro.com/newsletter/2024/11/weed-banking-hopes-rise-again-00190071">told</a> Politico they &#8220;still have hopes the cannabis banking bill can get done in the lame duck, despite the odds.&#8221; 
What Happened: Schumer, who brought the <a href="https://www.benzinga.com/topic/secure-and-fair-enforcement-safe-banking-act" target="_blank" rel="noreferrer noopener">Secure and Fair Enforcement Regulation (SAFER) Banking Act</a> (SAFER) to a <a href="https://www.benzinga.com/markets/cannabis/23/09/34929327/breaking-senate-committee-approves-cannabis-banking-reform-in-historic-vote">committee hearing</a> in September 2023, had intended to advance the bill by attaching it to must-pass legislation before the midterms. However, despite his vocal support, he did not call the bill for a full Senate vote, citing insufficient Republican backing to overcome filibuster rules. This hesitation, coupled with Democrats&#8217; shifting priorities after this month's <a href="https://www.benzinga.com/news/24/11/41768178/donald-trump-defeats-kamala-harris-to-win-2024-election">Republican electoral surge,</a> has all but killed hopes for cannabis banking reform during the lame-duck session.
And now, Senate Democrats are scrambling to address more immediate legislative tasks, including passing budget bills to avoid a looming <a href="https://www.benzinga.com/news/24/09/40931809/house-republicans-reject-their-own-funding-bill-as-government-shutdown-looms-mike-johnson-says-we-ha">Dec. 20 government shutdown</a> and finalizing judicial appointments before relinquishing control in January.
<h2 class="wp-block-heading">High Stakes As GOP Takes Congress</h2>
Senator <a href="https://www.benzinga.com/politics/24/11/41950681/trump-once-said-political-career-over-about-john-thune-now-senate-majority-leader-working-with-him-to-pass-gop-agenda">John Thune</a> of South Dakota who opposes marijuana legalization, is set to replace Sen. <a href="https://www.benzinga.com/topic/mitch-mcconnell" target="_blank" rel="noreferrer noopener">Mitch McConnell</a> as Senate majority leader. With Thune and conservative House Speaker Mike Johnson at the helm, the path to cannabis reform becomes even narrower. Johnson <a href="https://www.benzinga.com/markets/cannabis/23/10/35428675/buzz-kill-mike-johnsons-election-as-new-house-speaker-does-not-bode-well-for-cannabis-legalizati">has consistently voted against</a> most cannabis-related legislation, including banking reform.
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/11/41982165/new-gop-senate-leader-john-thune-opposes-marijuana-legalization-implications-for-banking-access-and-more">New GOP Senate Leader John Thune Opposes Marijuana Legalization: Implications For Banking Access And More</a>
Critics argue that Democrats, despite their rhetoric or best efforts, have fallen short of delivering substantive cannabis reform. Their missed opportunity leaves the industry bracing for continued financial instability.
Meanwhile, <a href="https://www.benzinga.com/24/11/42125955/cannabis-stocks-feel-the-burn-as-gaetz-bows-out-msos-in-focus">cannabis stocks tanked</a> last Thursday after pro-marijuana&nbsp;Matt Gaetz&nbsp;<a href="https://www.benzinga.com/24/11/42119848/matt-gaetz-withdraws-name-from-ag-nomination-calls-sex-trafficking-controversy-a-distraction" target="_blank" rel="noreferrer noopener">withdrew his nomination</a>&nbsp;for U.S. Attorney General and was replaced by the far less weed-friendly nominee Pam Bondi, a close associate of President-elect <a href="https://www.benzinga.com/topic/donald-trump">Donald Trump</a>.
<h2 class="wp-block-heading">Looking Ahead</h2>
As the likelihood of meaningful cannabis reform fades under the outgoing Democratic administration, advocates are left with no choice but to turn to the incoming Republican leadership, hoping they embrace the stance candidate Donald Trump <a href="https://www.benzinga.com/markets/cannabis/24/08/40561136/trump-dislikes-having-people-in-jail-for-cannabis-will-he-legalize-if-elected-or-just-trying-to-">expressed back in August</a> at his Mar-a-Lago residence. 
&#8220;As we legalize it, I start to agree a lot more because it&#8217;s being legalized all over the country,&#8221; the president-elect said.
Now Read: 
<ul>
<li><a href="https://www.benzinga.com/news/legal/24/11/42143770/trumps-pick-for-attorney-general-is-no-matt-gaetz-when-it-comes-to-cannabis-reform">Trump&#8217;s Pick for Attorney General Is No Matt Gaetz When It Comes To Cannabis Reform</a></li>
</ul>
Photo via Shutterstock

Cannabis

Government

Politics

Legal

GOP Takeover, Trump's Return Vs. Chuck Schumer's Last-Ditch Cannabis Banking Reform Push

CMAX

CareMax shares are trading lower after the company announced restructuring amidst its bankruptcy and delisting challenges.

Bath &amp; Body Works, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBWI#NYSE">BBWI</a>) shares are trading higher after the company reported better-than-expected <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/g42159938/bath-body-works-reports-third-quarter-2024-results" rel="noreferrer noopener">third-quarter results and raised its 2024 outlook</a>.
BBWI&#8217;s third-quarter adjusted earnings per share of 49 cents, beating the analyst consensus of 47 cents.
Quarterly sales of $1.610 billion, a growth of 3.1% year-over-year, above the street view of $1.579 billion.
The gross margin was 43.5%, down 20 bps YoY, and the operating margin was 13.5% compared to 14.2% YoY.
Related: <a target="_blank" href="https://www.benzinga.com/24/11/42131172/bath-here-are-the-recent-forecast-changes-from-wall-streets-most-accurate-analysts" rel="noreferrer noopener">Bath &amp; Body Works Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street&#8217;s Most Accurate Analysts</a>
&#8220;Innovation across our core products, adjacencies, and collaborations is resonating with both new and existing customers supported by the investments we have made in marketing and technology. We are capitalizing on our agile business model and predominantly U.S.-based supply chain, and we believe we are well-positioned to navigate a volatile retail environment and shorter holiday calendar,&#8221; commented Gina Boswell, CEO of Bath &amp; Body Works.
Net cash used for operating activities year-to-date totaled $69 million, compared to cash provided of $28 million a year ago.
Bath &amp; Body Works exited the quarter with cash and equivalents of $191 million. The company&#8217;s inventories as of quarter end totaled $1.178 billion, with long-term debt of $3.88 billion.
Bath &amp; Body Works had recently declared a regular quarterly dividend of&nbsp;$0.20&nbsp;per share, payable on December 6, 2024, to shareholders of record at the close of <a target="_blank" href="https://www.benzinga.com//node/41842833" rel="noreferrer noopener">business on November 22, 2024.</a>
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/downgrades/24/11/41855430/bath-body-works-stock-downgraded-due-to-this-risk-details" rel="noreferrer noopener">Bath &amp; Body Works Stock Downgraded Due To This Risk: Details</a>
Q4 Outlook: Bath &amp; Body Works projects net sales to decline of 6.5% to a decline of 4.5% year-over-year, reflecting a 500-basis-point headwind from a shifted fiscal calendar. Earnings per share are expected to be between $1.94 and $2.07, versus the $1.98 consensus.
2024 Outlook: The company raised fiscal 2024 guidance and now expects net sales to decline 2.5% &#8211; 1.7% (prior view: decline of 4% &#8211; 2%), including a 100-basis-point headwind from the 53rd week in 2023. Adjusted earnings per share are projected at $3.15&nbsp;&#8211; $3.28 <a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">(prior view $3.06&nbsp;&#8211; $3.26) versus the $3.18 consensus.</a>
Price Action: BBWI shares are trading higher by 19.2% at $36.61 premarket at the last check Monday.
Image via Unsplash

Earnings

Equities

Guidance

Dividends

BBWI

Bath & Body Works Delivers Growth Amid Challenges, Beats Q3 Expectations And Lifts 2024 Projections

STKH

UMAMI Bioworks And Steakholder Foods Partner To Scale 3D-Printed Fish Fillets For Global Commercialization

On CNBC's &#8220;Mad Money Lightning Round,&#8221; Jim Cramer recommended buying BHP Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BHP#NYSE">BHP</a>), adding that it's a &#8220;very <a href="https://www.benzinga.com/24/11/42084529/bhp-unveils-14-billion-capex-for-chilean-copper-operations">well-run&#8221; company.</a>
On Nov. 20, BHP announced plans to invest up to $14 billion to enhance its copper production in Chile, as revealed during a three-day site tour of its operations. This substantial capital expenditure aims to secure the long-term future of its assets in the region and support the growing global demand for copper.
Cramer said Diamondback Energy, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FANG#NASDAQ">FANG</a>) is a buy.
On Nov. 4, Diamondback Energy reported quarterly earnings of $3.38 per share, which missed the analyst consensus estimate of $3.99 per share. The company reported quarterly sales of $2.65 billion which beat the analyst consensus estimate of $2.44 billion.
When asked about AMC Entertainment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMC#NYSE">AMC</a>), he said, &#8220;If it gets to six, I want you to sell it. Period. End of story.&#8221;
On Nov. 12, the company disclosed a debt retirement move in a SEC filing. The company said it entered into a series of privately negotiated agreements to retire $24.22 million in unsecured debt through 5.75% subordinated notes due 2025 <a href="https://www.benzinga.com/trading-ideas/movers/24/11/41952040/amc-entertainment-shares-are-on-the-rise-today-whats-going-on">between Nov. 8 and Nov. 12</a>.
Copart, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPRT#NASDAQ">CPRT</a>) is a &#8220;remarkable&#8221; company, Cramer said. &#8220;I need to see a pullback in Copart.&#8221;
On Nov. 21, Copart reported better-than-expected sales results for the first quarter.
Price Action:
<ul>
<li>BHP Group shares gained 0.7% to settle at $52.36 on Friday.</li>
<li>Diamondback Energy shares gained 1.4% to close at $185.29.</li>
<li>AMC Entertainment shares gained 1.3% to close at $4.55.</li>
<li>Copart shares jumped 10.2% to settle at $62.70 during the session.</li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/24/11/42137942/jim-cramer-says-this-stock-is-a-bitcoin-play-and-he-prefers-to-own-bitcoin">Jim Cramer Says This Stock Is A Bitcoin Play And He Prefers To Own Bitcoin</a></li>
</ul>

Long Ideas

Media

CPRT

FANG

Jim Cramer: Copart Is 'Remarkable,' BHP Is 'Well-Run,' Buy This Energy Stock

Contracts

Actelis Networks Announces Two Expansion Orders For The Washington DC Department Of Transportation, Terms Not Disclosed

TDOC

Teladoc Health Launches New AI-Capabilities To Enhance Virtual Sitter Solution To Improve Patient Safety

ONCT

Oncternal Therapeutics shares are trading lowers after the company announced that NASDAQ plans to delist its stock.

APLM

Trading Halt: Halt status updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times

UFPI

UFP Packaging Opens Facility In Newnan, GA

ICCT

iCoreConnect Expands Partnership With Maryland State Dental Association To Include Its Full Platform Of Cloud-based Software And Technology Solutions.

Lakeside Holding's Hupan Pharmaceutical Partners With  Sinopharm Group Hubei.

TD Cowen analyst Andrew Charles maintains Domino's Pizza (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DPZ#NYSE">DPZ</a>) with a Buy and raises the price target from $475 to $515.

TD Cowen Maintains Buy on Domino's Pizza, Raises Price Target to $515

Goldman Sachs analyst Robert Cox downgrades Arthur J. Gallagher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AJG#NYSE">AJG</a>) from Buy to Neutral and maintains the price target from $313 to $313.

Goldman Sachs Downgrades Arthur J. Gallagher to Neutral, Maintains Price Target to $313

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Wedbush analyst Daniel Ives upgraded the rating for Snowflake Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNOW#NYSE">SNOW</a>) from Neutral to Outperform and announced a $190 price target. Snowflake shares closed at $167.44 on Friday. <a href="https://www.benzinga.com/quote/SNOW/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>DA Davidson analyst Linda Bolton Weiser upgraded The Procter &amp; Gamble Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PG#NYSE">PG</a>) from Neutral to Buy and raised the price target from $160 to $209. Procter &amp; Gamble shares closed at $176.28 on Friday. <a href="https://www.benzinga.com/quote/PG/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Wolfe Research analyst Andrew Rosivach upgraded the rating for Jones Lang LaSalle Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JLL#NYSE">JLL</a>) from Peer Perform to Outperform and announced a $353 price target. Jones Lang LaSalle shares closed at $263.27 on Friday. <a href="https://www.benzinga.com/quote/JLL/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Citigroup analyst Keith Horowitz upgraded U.S. Bancorp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USB#NYSE">USB</a>) from Neutral to Buy and boosted the price target from $49 to $65. U.S. Bancorp shares closed at $52.49 on Friday. <a href="https://www.benzinga.com/quote/USB/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Goldman Sachs analyst Robert Cox upgraded the rating for W. R. Berkley Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WRB#NYSE">WRB</a>) from Neutral to Buy and announced a $69 price target. WR Berkley shares closed at $62.27 on Friday. <a href="https://www.benzinga.com/quote/WRB/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying SNOW stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="586" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25084918/image-267-1024x586.png" alt="" class="wp-image-663381" style="width:637px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25084918/image-267-1024x586.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25084918/image-267-300x172.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25084918/image-267-768x440.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25084918/image-267.png 1121w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/24/11/42137942/jim-cramer-says-this-stock-is-a-bitcoin-play-and-he-prefers-to-own-bitcoin">Jim Cramer Says This Stock Is A Bitcoin Play And He Prefers To Own Bitcoin</a></li>
</ul>

Upgrades

SNOW

This Snowflake Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates Longeveron (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGVN#NASDAQ">LGVN</a>) with a Buy and maintains $10 price target.

Reiteration

HC Wainwright & Co. Reiterates Buy on Longeveron, Maintains $10 Price Target

RenovoRx files to sell 6.96M shares of common stock for holders

Renovorx, Inc. (RNXT) has disclosed a new risk, in the Accounting & Financial Operations category. Renovorx, Inc., a clinical-stage biopharmaceutic...

Biopharmaceutical Challenger Renovorx: Navigating Uncertainty and Financial Risks in Drug Development

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
RenovoRx (NASDAQ:<a href="https://investorplace.com/stock-quotes/rnxt-stock-quote/">RNXT</a>) just reported results for the first quarter of 2024.<ul><li>RenovoRx reported earnings per share of -7 cents. This was above the analyst estimate for EPS of -16 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/05/rnxt-stock-earnings-renovorx-for-q1-of-2024/">RNXT Stock Earnings: RenovoRx Beats EPS for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

RNXT Stock Earnings: RenovoRx Beats EPS for Q1 2024

RenovoRx (RNXT) just unveiled an announcement. At the 2024 annual meeting, the Company successfully elected six directors to a one-year term with o...

RenovoRx Shareholders Unanimously Elect Board Directors

Edward Woo, an analyst from Ascendiant, has initiated a new Buy rating on RenovoRx (RNXT). Edward Woo has given his Buy rating due to a combination...

Buy Rating Endorsed for RenovoRx: Innovative TAMP Platform and Promising RenovoGem Trials

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
RenovoRx (NASDAQ:<a href="https://investorplace.com/stock-quotes/rnxt-stock-quote/">RNXT</a>) just reported results for the second quarter of 2024.<ul><li>RenovoRx reported earnings per share of -10 cents. This met the analyst estimate for EPS of -10 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/rnxt-stock-earnings-renovorx-for-q2-of-2024/">RNXT Stock Earnings: RenovoRx Meets EPS for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

RNXT Stock Earnings: RenovoRx Meets EPS for Q2 2024

Maxim Group analyst Jason McCarthy maintained a Buy rating on RenovoRx (RNXT – Research Report) yesterday and set a price target of $4.00. Jason Mc...

Buy Rating Backed by RenovoRx's Clinical Advancements and Sustained Financial Health

RenovoRx reports Q3 results

Jason McCarthy, an analyst from Maxim Group, maintained the Buy rating on RenovoRx (RNXT – Research Report). The associated price target is $4.00. ...

Positive Outlook for RenovoRx: Promising TIGeR-PaC Phase 3 Trial Results and Innovative Drug Delivery Platform Drive Buy Rating

RenovoRx (RNXT) announced that the Northwell Health Cancer Institute, NHCI, in New Hyde Park, NY is enrolling patients with locally advanced pancre...

RenovoRx announces NHCI is enrolling patients for Phase III TIGeR-PaC trial

Management

Press Releases

RenovoRx Appoints Ryan Witt as Senior Vice President, Head of Corporate Strategy and Partnerships

University of Nebraska Medical Center Launches Patient Enrollment for RenovoRx's Pivotal Phase III TIGeR-PaC Clinical Trial

Health Care

RenovoRx Announces Acceptance for Publication in the International Peer-Reviewed Journal, The Oncologist®

RenovoRx Announces Publication of Positive Early-Stage Clinical Data in International Peer-Reviewed Journal, The Oncologist®

RenovoRx Announces First Patient Enrolled at University of Nebraska Medical Center for the Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial

RenovoRx CEO Shaun Bagai to Present at H.C. Wainwright's 26th Annual Global Investment Conference on September 9, 2024 in New York

RenovoRx Announces Presentation at Symposium on Clinical Interventional Oncology Highlighting TAMP™ for Targeted Treatment of Locally Advanced Pancreatic Cancer

General

RenovoRx Increases Production of FDA-Cleared RenovoCath® Delivery System in Response to Strong Demand from Oncology and Interventional Radiology Physicians

RenovoRx Reports Third Quarter 2024 Financial Results and Operational Highlights

Northwell Health Cancer Institute Launches Patient Enrollment in RenovoRx's Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial

Comments

RenovoRx

RenovoRx (RNXT) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga